Boston ScientificMEX:BSX -1.81%85 Days Payable is 65.52 as of Mar. 2026, which is 4% above its 10-year median of 63.00. GuruFocus rates MEX:BSX with a GF Score™ of 85/100 and a GF Value™ of MXN1,851.91 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, Boston Scientific ranks worse than 57.99% on this metric.
The historical rank and industry rank for Boston Scientific's Days Payable or its related term are showing as below:
MEX:BSX'
s Days Payable Range Over the Past 10 Years
Min: 47.83 Med: 63 Max: 76.41
Current: 60.31
During the past 13 years, Boston Scientific's highest Days Payable was 76.41. The lowest was 47.83. And the median was 63.00.
MEX:BSX's Days Payable is ranked worse than 57.99% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs MEX:BSX: 60.31
Boston Scientific's Days Payable
increased
from Mar. 2025 (62.26) to Mar. 2026 (65.52).
It may suggest that Boston Scientificdelayed paying its suppliers.
Boston Scientific Days Payable Related Terms
Boston Scientific Days Payable Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boston Scientific's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Days Payable distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Boston Scientific's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (MEX:BSX) has a Days Payable of 65.52 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Boston Scientific and its competitors. This is near median its historical median of 63.00. Over the past decade, Boston Scientific's Days Payable has ranged from 47.83 to 76.41. According to the industry distribution chart, Boston Scientific ranks #461 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 58%.
Is Boston Scientific's Days Payable too high?
Boston Scientific's current Days Payable of 65.52 is near median its 10-year median of 63.00. Over the past 10 years, this metric has ranged from a low of 47.83 to a high of 76.41. The Medical Devices & Instruments industry median Days Payable is 68.07. Boston Scientific's value of 65.52 is 3.7% below this industry median. Based on the distribution chart, Boston Scientific ranks #461 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boston Scientific has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Days Payable compare to EW and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #461 out of 795 companies for Days Payable. This places Boston Scientific in the lower half of its industry. The industry median Days Payable is 68.07. Boston Scientific's value of 65.52 is 3.7% below this benchmark. Historically, Boston Scientific's own Days Payable has ranged from 47.83 to 76.41 over the past decade. While the company's 10-year median is 63.00 vs. the industry median of 68.07, Boston Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boston Scientific's current Days Payable of 65.52 is 3.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Boston Scientific and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boston Scientific's current Days Payable is 65.52, which is near median its own 10-year median of 63.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,851.91, compared to a current price of MXN745.23 — trading 59.8% below its estimated fair value. The current Days Payable is 65.52, which is near median its 10-year median of 63.00 and 3.7% below the Medical Devices & Instruments industry median of 68.07. Boston Scientific's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current Days Payable is 65.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (MEX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of MXN745.23 is trading 59.8% below its estimated GF Value™ of MXN1,851.91.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for MEX:BSX:
Days Payable: 65.52 (near median its 10-year median of 63.00)
GF Value™: MXN1,851.91 vs. price of MXN745.23 (59.8% below fair value)
Industry Position: 3.7% below the Medical Devices & Instruments median (#461 of 795)
No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
85GF Score
Get the complete analysis for MEX:BSX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BSX has been successfully added to your 
